Structures by: Cai Z. Q.
Total: 9
<i>N</i>-[(6-Bromo-2-methoxy-3-quinolyl)phenylmethyl]-2-morpholino- <i>N</i>-(1-phenylethyl)acetamide
C31H32BrN3O3
Acta Crystallographica Section E (2009) 65, 8 o1901
a=7.8696(14)Å b=9.4558(16)Å c=9.8018(17)Å
α=90.544(2)° β=100.562(3)° γ=104.618(2)°
<i>N</i>-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine
C21H14ClFIN3O
Acta Crystallographica Section E (2010) 66, 7 o1810
a=13.128(3)Å b=7.6293(15)Å c=18.898(4)Å
α=90.00° β=90.00° γ=90.00°
(2<i>R</i>,4<i>R</i>)-1-(<i>tert</i>-Butoxycarbonyl)-4-methoxypyrrolidine-2- carboxylic acid
C11H19NO5
Acta Crystallographica Section E (2010) 66, 12 o3258
a=6.4299(13)Å b=9.784(2)Å c=10.279(2)Å
α=90.00° β=90.12(3)° γ=90.00°
<i>N</i>-(2-Hydroxy-5-nitrophenyl)methanesulfonamide ethanol monosolvate
C7H8N2O5S,C2H6O
Acta Crystallographica Section E (2011) 67, 6 o1383
a=11.709(3)Å b=8.8521(18)Å c=12.439(3)Å
α=90.00° β=112.459(7)° γ=90.00°
4-(3-Fluoro-4-nitrophenyl)morpholin-3-one
C10H9FN2O4
Acta Crystallographica Section E (2011) 67, 6 o1549
a=6.6408(7)Å b=7.3788(10)Å c=10.8546(14)Å
α=73.30(3)° β=75.39(3)° γ=74.30(3)°
1-(2,4-Dichlorophenyl)-5-(2-nitroanilino)-1<i>H</i>-pyrazole-4-carbonitrile
C16H9Cl2N5O2
Acta Crystallographica Section E (2012) 68, 4 o1142
a=13.878(3)Å b=13.475(3)Å c=17.421(4)Å
α=90.00° β=90.00° γ=90.00°
3-(2,4-Dichlorophenyl)-5-(4-fluorophenyl)-2-methyl-7- (trifluoromethyl)pyrazolo[1,5-<i>a</i>]pyrimidine
C20H11Cl2F4N3
Acta Crystallographica Section E (2012) 68, 5 o1515
a=9.5361(19)Å b=15.941(3)Å c=24.853(5)Å
α=90.00° β=90.00° γ=90.00°
3-(2,4-Dichlorophenyl)-5-(4-fluorophenyl)-2-phenyl-7- (trifluoromethyl)pyrazolo[1,5-<i>a</i>]pyrimidine
C25H13Cl2F4N3
Acta Crystallographica Section E (2012) 68, 6 o1923
a=9.0826(18)Å b=9.0606(18)Å c=27.259(6)Å
α=90.00° β=99.46(3)° γ=90.00°
Dabigatran etexilate tetrahydrate
C34H41N7O5,4(H2O)
Acta Crystallographica Section E (2012) 68, 12 o3385
a=9.1140(13)Å b=10.9700(14)Å c=18.3830(17)Å
α=88.510(10)° β=85.455(9)° γ=83.034(12)°